OIG Calls PODs "Inherently Suspect"

by Baker Donelson

This article also appeared in Health Lawyers Weekly, a publication of the American Health Lawyers Association.

Making its most strongly worded statement to date, the Department of Health and Human Services Office of Inspector General (OIG) issued a Special Fraud Alert on Physician-Owned Entities on March 26, 2013, calling physician-owned distributors (PODs) “inherently suspect” under the federal Antikickback Statute. The OIG describes a number of suspect attributes of PODs and identifies additional factors that may magnify its concerns about them. The OIG also states that the Special Fraud Alert is “not intended to serve as a blueprint for how to structure a lawful POD, as an arrangement may not exhibit any of the … suspect characteristics and yet still be found to be unlawful.” Significantly, the OIG warns hospitals and ambulatory surgery centers (ASCs) that they may be at risk for purchasing from physician-owned entities in an attempt to maintain or secure referrals from physician-owners of PODs.

The direct and negative tone of the Special Fraud Alert is a departure from the OIG’s prior statements on PODs that were both more general and less critical. The OIG cites its 1989 Special Fraud Alert on Joint Venture Arrangements as establishing a long-standing concern about physician investment in entities to which they refer. The OIG also cites its October 6, 2006, letter as recommending close scrutiny of physician investments in medical device manufacturers and distributors.

Although it is well known that the Senate Finance Committee is conducting an ongoing investigation into the proliferation of various physician-owned entities, it is less clear whether that effort may have pressured the OIG to provide more detailed guidance. Letters were exchanged between the Senate Finance Committee, the OIG, and the Centers for Medicare & Medicaid Services (CMS) in 2011. In letters to CMS and the OIG, the Senate Finance Committee raised concerns about the adequacy of existing guidance on PODs. The OIG responded that it was studying the issue, but expressed uncertainty about its ability to issue further guidance given the variability of physician-owned entities. As part of its study of PODs, the OIG has requested information from various hospitals regarding their relationships with PODs. This Special Fraud Alert appears to have been issued before the OIG finalized its review of the responses.

The Special Fraud Alert defines PODs as any physician-owned entity that derives revenue from selling, or arranging for the sale of, implantable medical devices and includes physician-owned entities that “purport” to design or manufacture, typically under contractual arrangements, their own medical devices or instrumentation. The OIG notes that the guidance applies regardless of whether the entity is called a POD, a physician-owned company, or something else. The OIG also notes that while the Special Fraud Alert focuses on arrangements involving implantable medical devices because they are typically physician preference items, the same principles apply to other types of physician-owned entities.

The OIG begins its analysis by reiterating its long-standing guidance that the opportunity for a referring physician to earn a profit could constitute illegal remuneration under the Antikickback Statute. The OIG cites three questionable features of physician-investment arrangements: (1) selecting investors because they are in a position to generate substantial business, (2) requiring investors who cease practicing in the service area to divest their investment, and (3) distributing extraordinary returns compared to the risk.

In a variety of contexts, the OIG cites to seven concerns that the Antikickback Statute is designed to address – namely, additional costs, overutilization, quality of care, access to care, patient’s freedom of choice, competition, and professional judgment. In the Special Fraud Alert, the OIG warns that PODs raise four of these concerns – corruption of medical judgment, overutilization, increased costs to federal healthcare programs, and unfair competition.

Citing a prior discussion of the limitations of patient disclosure in the context of the ASC safe harbor, the OIG warns that disclosure to patients of a physician’s financial interest in a POD is not sufficient to protect those patients from the dangers of conflicts of interest. In fact, the OIG raises the concern that patient disclosures are often viewed more as a “testimonial,” rather than as a legitimate effort to raise the potential conflict of interest issue.

In stopping short of declaring all PODs unlawful, the OIG acknowledges that the ultimate decision of whether a POD violates the Antikickback Statute depends on the intent of the parties. However, the OIG identifies eight suspect characteristics it associates with PODs:

  1. The size of investment offered to physicians varies with expected or actual volume or value of referrals.
  2. Distributions are not in proportion to ownership interests or physicians pay different prices for their ownership interests due to the volume or value of devices used by the physician.
  3. Physician-owners condition referrals to hospitals or ASCs on the purchase and use of devices from their POD. The OIG recognizes that such pressure may be explicit or implicit and could include exclusive purchase arrangements.
  4. Physician-owners are required, pressured, or actively encouraged to refer or are punished for failing to use their POD’s devices.
  5. The POD retains the right to repurchase the interest of a physician-owner if the physician is unable to refer due to relocation, retirement, or otherwise.
  6. The POD is a shell and does not conduct appropriate product evaluations, maintain sufficient inventory, or employ (or contract with) necessary personnel.
  7. The POD does not maintain continuous oversight of all distribution functions.
  8. Physician-owners fail to disclose or conceal their ownership interest in a POD from hospitals and ASCs that require conflict-of-interest disclosures.

According to the OIG, the presence of any of these suspect characteristics is concerning. As noted above, the OIG also warns that the suspect characteristics are not meant as a blueprint for structuring lawful PODs and that PODs that do not exhibit any of these suspect characteristics may still be unlawful.

The OIG identifies two situations in which its concerns about PODs may be magnified: (1) where the physician-owners are few in number so the volume or value of a physician-owner’s referrals tracks the physician-owner’s return on investment and (2) where the physician-owners change their behavior either shortly before or after investing in a POD.

Recognizing that some PODs “purport” to design or manufacture devices, the OIG warns that claims of superiority of devices by physician-owners do not necessarily avoid unlawful intent. The OIG is especially concerned about unsubstantiated claims about devices. The OIG cautions that the risk is particularly high for PODs whose devices are used solely by their physician-owners.

In an effort to address both sides of POD arrangements and perhaps to create more pressure for change, the OIG warns hospitals and ASCs that they also may be at risk for purchasing from physician-owned entities, if doing so constitutes an attempt to maintain or secure referrals from the physician-owners of the physician-owned entities.

Ober|Kaler's Comments

In light of the negative views expressed by the OIG in the Special Fraud Alert on Physician-Owned Entities, arrangements involving PODs should be carefully considered. This review should be conducted by the physician-owners of existing PODs, as well as by hospitals and ASCs that currently purchase items, particularly implantable medical devices, from PODs.

As physicians, hospitals, and others re-evaluate existing arrangements, many tough questions will be presented. Should physician-owners sell their interest in PODs? Who will buy their interests and how will they be valued in light of the OIG’s position? Should (must?) hospitals immediately terminate arrangements with PODs? What additional due diligence should hospitals conduct on their existing arrangements with PODs? In light of the OIG’s statement that the same analysis may apply to other physician-owned entities, should hospitals and ASCs also review their current arrangements with such entities?

Over the years, the OIG has issued numerous Special Fraud Alerts, Special Advisory Bulletins, and other industry guidance. This Special Fraud Alert, however, seems to be different in its scope and tone. Specifically, it appears to be considerably more negative and evidences, at least in our view, a clear signal from the OIG that the structure and operation of PODs, as well as arrangements to purchase from PODs, may be subject to significant, and focused, scrutiny going forward.


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Baker Donelson | Attorney Advertising

Written by:

Baker Donelson

Baker Donelson on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.